Prognostic interaction between thrombocytosis and JAK2 V617F mutation in the WHO subcategories of myelodysplastic/myeloproliferative disease-unclassifiable and refractory anemia with ringed sideroblasts and marked thrombocytosis-Reference-Cited by-同舟云学术

Prognostic interaction between thrombocytosis and JAK2 V617F mutation in the WHO subcategories of myelodysplastic/myeloproliferative disease-unclassifiable and refractory anemia with ringed sideroblasts and marked thrombocytosis

Published:2007-12-06 Issue:6 Volume:22 Page:1295-1298
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Atallah E,Nussenzveig R,Yin C C,Bueso-Ramos C,Tam C,Manshouri T,Pierce S,Kantarjian H,Verstovsek S

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/2405054.pdf

Reference8 articles.

1. Jaffe ES, Harris NL, Stein H, Vardiman J . Pathology and genetics. Tumours of Haematopoietic and Lymphoid tissues, 3rd edn. IARC: Lyon, Cedex, France, 2001, 58–59.

2. Boissinot M, Garand R, Hamidou M, Hermouet S . The JAK2-V617F mutation and essential thrombocythemia features in a subset of patients with refractory anemia with ring sideroblasts (RARS). Blood 2006; 108: 1781–1782.

3. Renneville A, Quesnel B, Charpentier A, Terriou L, Crinquette A, Lai JL et al. High occurrence of JAK2 V617 mutation in refractory anemia with ringed sideroblasts associated with marked thrombocytosis. Leukemia 2006; 20: 2067–2070.

4. Szpurka H, Tiu R, Murugesan G, Aboudola S, Hsi ED, Theil KS et al. Refractory anemia with ringed sideroblasts associated with marked thrombocytosis (RARS-T), another myeloproliferative condition characterized by JAK2 V617F mutation. Blood 2006; 108: 2173–2181.

5. Wang SA, Hasserjian RP, Loew JM, Sechman EV, Jones D, Hao S et al. Refractory anemia with ringed sideroblasts associated with marked thrombocytosis harbors JAK2 mutation and shows overlapping myeloproliferative and myelodysplastic features. Leukemia 2006; 20: 1641–1644.

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. In the Pipeline: Emerging Therapy for MDS and MDS/MPN;Pathogenesis and Treatment of Leukemia;2023

2. Hybrid or Mixed Myelodysplastic/Myeloproliferative Disorders – Epidemiological Features and Overview;Frontiers in Oncology;2021-11-16

3. Genetic Aspects of Myelodysplastic/Myeloproliferative Neoplasms;Cancers;2021-04-27

4. Philadelphia-Negative Myeloproliferative Neoplasms: Laboratory Workup in the Era of Next-Generation Sequencing;Current Hematologic Malignancy Reports;2019-08-06

5. Treatment of myelodysplastic syndrome in the era of next‐generation sequencing;Journal of Internal Medicine;2019-03-19